A Los Angeles Jury Said “Not Negligent” — Your Family’s Talc Case Is Not Over
You are reading about this verdict at the worst possible hour. Someone you love used Johnson’s Baby Powder for years — maybe decades — and then ovarian cancer took her. You found a lawyer, or you were about to. And now the headline says a Los Angeles jury sided with the company. Ten of twelve jurors said Johnson & Johnson was not negligent. The company’s litigation leadership called the plaintiffs’ evidence “junk science.” And you are sitting at a kitchen table wondering whether any of this is still worth pursuing.
It is. We are going to tell you exactly why, and exactly what this one verdict does and does not mean for families like yours — honestly, without pretending a defense verdict is a victory, and without pretending it is the end.
Here is the first thing to understand: this was one trial, in one courtroom, with three specific wrongful death claims, tried on one specific legal theory — negligence — in front of one specific jury. Over 67,000 talc cases remain pending against Johnson & Johnson across the country. The company has won some trials and lost others. The litigation is not over. The science is not settled. And the evidence that decides whether your family’s case is strong or weak is fading right now — product containers being discarded, medical records aging toward destruction, and family memories of talc-use habits degrading with every month that passes.
We handle toxic tort and product liability cases and wrongful death claims, and we are writing this page as the senior trial team that takes California cases — to give you the education, the governing law, the evidence clocks, and the honest case-value evaluation you need right now. We were not counsel in this Los Angeles trial. We are the resource that helps families in your position understand what just happened and what to do about it. The call is free. The consultation is free. And we do not get paid unless we win your case.
What the Jury Found — and What They Did Not Decide
On a Friday in June 2026, a jury in the Superior Court of California, County of Los Angeles — the largest trial court system in the United States — returned a defense verdict for Johnson & Johnson in a wrongful death action brought by the families of three women who died of ovarian cancer after long-term use of talc-based baby powder. Ten of twelve jurors found that J&J was not negligent in manufacturing and selling cosmetic talc products. Two jurors disagreed.
That is what the jury decided. Now let us tell you what they did not decide — because the difference matters enormously.
The jury was asked about negligence. Negligence means the company failed to act with reasonable care — that it did something a reasonably careful company would not have done, or failed to do something a reasonably careful company would have done. To find J&J negligent, the jury had to be persuaded that the company knew or should have known about the ovarian cancer risk and failed to act on that knowledge.
But California law gives plaintiffs another path that was not the primary theory tried here: strict products liability. Under California’s Greenman doctrine — a landmark doctrine that changed American product liability law — a manufacturer can be held liable for a defective product without any proof of negligence at all. The question under strict liability is not “was the company careless?” but “was the product defective?” — either because its design was unreasonably dangerous, because it failed to carry adequate warnings, or because it was manufactured incorrectly.
Why does this matter? Because a negligence verdict for the defense does not necessarily mean the jury found the product safe. It may mean the jury was not persuaded the company was careless in a specific, legally cognizable way. A strict liability failure-to-warn claim asks a different question: should the company have warned consumers about a possible cancer risk? The standard is different. The burden of proof is different. And the evidence that wins a negligence case is not always the same evidence that wins a strict liability case.
The fact that this case appears to have been tried and lost on negligence is a strategic signal — one that experienced talc litigators are studying right now. It suggests that in future trials, plaintiffs may front-load strict liability failure-to-warn theories alongside or instead of negligence, because strict liability may present a more favorable liability framework in ovarian cancer talc cases.
The Causation Battleground — Why Ovarian Cancer Talc Cases Are Harder Than Mesothelioma Cases
If you want to understand why some talc cases win and some lose, you need to understand the single hardest fight in the courtroom: causation. Not whether the company was careless — but whether the product actually caused the cancer.
Johnson & Johnson has settled a majority of the cases alleging its talc products caused mesothelioma — a rare, almost signature cancer of the lining of the lungs and abdomen, associated with asbestos exposure. Nearly all of the remaining cases — the 67,000-plus still pending — allege that talc products cause ovarian cancer. That shift is not accidental. It reflects the relative strength of the causal link.
Mesothelioma is what lawyers call a signature disease. It is so strongly associated with asbestos exposure that a diagnosis of mesothelioma is itself near-conclusive evidence that the person was exposed to asbestos. If a talc product was contaminated with asbestos, and the user developed mesothelioma, the causal chain is comparatively short and powerful.
Ovarian cancer is different. It is not a signature disease for talc. It has many known risk factors — genetic mutations (BRCA1 and BRCA2), family history, age, nulliparity (never having given birth), endometriosis, hormone therapy, obesity, and others. A woman who used talc and developed ovarian cancer may also carry a BRCA mutation she never knew about. The defense will find that alternative explanation and put it in front of the jury.
The plaintiff must prove two things: general causation (talc use can cause ovarian cancer) and specific causation (talc use caused THIS woman’s ovarian cancer). Both are fought with experts — epidemiologists who study population-level cancer patterns, gynecologic oncologists who understand the biological mechanism, and toxicologists who can explain how talc particles might travel from the perineal area to the ovaries.
The International Agency for Research on Cancer has classified perineal use of talc-based body powder as “possibly carcinogenic to humans” (Group 2B).
That classification — from the world’s leading cancer-research agency — is a tool plaintiff experts use to support general causation. But note the word “possibly.” Group 2B is not the highest classification. Group 1 means the agency is certain the substance causes cancer in humans. Group 2B means the evidence is limited but suggestive. The defense will emphasize that lower classification level every time.
The biological plausibility argument is the second front. Plaintiff experts must articulate a mechanism: how do talc particles travel from the vagina, through the cervix and uterus, up the fallopian tubes, to the ovaries? The defense argues this pathway is unproven or implausible. The plaintiff’s experts counter with studies showing talc particles have been found in ovarian tissue, and with the inflammatory response theory — that talc particles in the pelvic cavity trigger chronic inflammation that promotes cancer development.
This is the battleground. It is not a yes-or-no question. It is a room full of experts, charts, studies, and cross-examination — and different juries in different cities reach different conclusions. That is why the trial record is mixed.
J&J’s Mixed Trial Record — Wins and Losses Across Jurisdictions
The Los Angeles defense verdict is not an anomaly. It is part of a pattern — and the pattern cuts both ways.
Johnson & Johnson has won trials in multiple jurisdictions, including a verdict in Oklahoma the week before this Los Angeles trial. The company has demonstrated that when it can persuade a jury that the causation evidence is weak, it walks away paying nothing.
But J&J has also lost — badly. In what remains the largest talc verdict in the litigation’s history, a Missouri jury awarded 22 women who alleged talc caused their ovarian cancer $4.69 billion in July 2018. On appeal, the Missouri Court of Appeals reduced that verdict to approximately $2.12 billion. The United States Supreme Court declined to review the case in June 2021 — meaning the reduced $2.1 billion award stood as final. That is not a press release. That is a number the highest court in the country let stand.
The range is extreme: from zero (as in this Los Angeles trial) to over $2 billion affirmed on appeal. The variance is driven by the quality of general and specific causation proof, the persuasiveness of internal corporate documents, the number of plaintiffs, the venue, and the specific legal theories pleaded. This is why we say the outcome of one trial does not foreclose the viability of comparable claims in different venues with different evidence.
The 67,000 Pending Cases — and J&J’s Three Failed Bankruptcy Attempts
Johnson & Johnson faces over 67,000 plaintiffs alleging its baby powder and other talc products cause ovarian cancer. That number tells you something important: this litigation is not winding down because of one defense verdict. It is massive, it is ongoing, and the company has been trying to find a way out of it for years.
J&J’s most aggressive strategy was the so-called “Texas two-step” — a corporate maneuver in which a company splits into two entities, one holding the valuable business and the other holding the liability, and then pushes the liability entity into bankruptcy to force a global settlement. J&J created LTL Management LLC to hold its talc liability and filed it for Chapter 11. That filing was dismissed. J&J tried again. Dismissed again. A third attempt through a renamed entity called Red River Talc LLC was also dismissed — on March 31, 2025, the Bankruptcy Court for the Southern District of Texas denied confirmation and dismissed the case, citing vote-solicitation irregularities and impermissible nonconsensual third-party releases.
Three times the company tried to wall these cases off inside a bankruptcy it manufactured for that purpose. Three times a court threw it out. The cases are back in the tort system — where trials have resumed, where some plaintiffs win, and where the company must face juries one courtroom at a time.
The corporate structure matters because it affects who you sue and who pays. Johnson & Johnson Consumer Inc. was the historical talc seller. Kenvue Inc. — the consumer-health spinoff that now owns brands like Band-Aid and Tylenol — is a separate public company, though J&J retains indemnity arrangements. The shell game of entities, subsidiaries, and bankruptcy vehicles is designed to put distance between the injured and the deep pocket. Understanding that structure is part of building a case that actually reaches the money.
California’s Product Liability Law — Your Strongest Tools
If your case would be filed in California, you have advantages that plaintiffs in some other states do not. Here is what California law gives you — and what it does not.
Strict products liability under the Greenman doctrine. California was one of the first states to adopt strict products liability — the rule that a manufacturer is responsible for a defective product regardless of whether it was negligent. Under this doctrine, you do not have to prove the company was careless. You have to prove the product was defective — that it was unreasonably dangerous for its intended use, or that it lacked adequate warnings about a known risk. California applies both the consumer-expectation test (did the product perform as safely as an ordinary consumer would expect?) and the risk-benefit test (do the risks of the design outweigh its benefits?) for design defect claims.
No non-economic damage caps in product liability cases. California’s Medical Injury Compensation Reform Act — known as MICRA — caps non-economic damages in medical malpractice cases. But MICRA does not apply to product liability cases. There is no statutory cap on pain and suffering, loss of consortium, or other non-economic damages in a talc product liability case filed in California. This is a significant advantage over states that cap non-economic damages across all personal injury cases.
Punitive damages. California allows punitive damages upon a showing of malice, oppression, or fraud. In talc litigation, punitive damages theories rest on internal corporate documents — memoranda, emails, testing results, and strategy papers suggesting the company knew of contamination concerns or cancer risk and chose not to warn consumers. Prior talc verdicts nationally have included significant punitive awards based on such internal documents. The $2.1 billion affirmed Ingham verdict included a substantial punitive component. In this Los Angeles case, the jury’s negligence finding for the defense precluded any damages recovery — but in a case where causation is established and internal documents are persuasive, punitive damages remain available in California.
Wrongful death and survival actions. California treats a death as two separate claims. A wrongful death action belongs to the surviving family members and compensates their losses — lost financial support, funeral and burial expenses, and loss of society, comfort, and consortium. A survival action belongs to the decedent’s estate and captures what the victim endured before death — pre-death pain and suffering and medical expenses. Both tracks are available in a talc-ovarian cancer wrongful death case.
Pure comparative negligence. California follows pure comparative negligence, meaning your recovery is reduced by your share of fault but never automatically erased — even if you were 99 percent at fault, you could theoretically recover 1 percent. In product liability cases involving multiple defendants, Proposition 51 apportions non-economic damages by several liability rather than joint and several liability — meaning each defendant pays only its own share of non-economic damages, not the entire amount.
The statute of limitations. California’s statute of limitations for wrongful death is generally two years from the date of death. But in toxic exposure cases, the discovery rule and tolling doctrines may affect timing — the clock may not start until the plaintiff knew or reasonably should have known that the exposure caused the disease. This is a critical issue in talc cases because the latency between exposure and cancer diagnosis can span decades. You must confirm the current California rule for your specific filing date with an attorney immediately — because the deadline is jurisdiction-specific and the consequences of missing it are final.
The Sargon standard for expert admissibility. California courts apply the Sargon standard for the admissibility of expert testimony — California’s version of the federal Daubert reliability test. Your experts’ methodology must satisfy this standard, and the defense will challenge it. Early engagement of board-certified epidemiologists and gynecologic oncologists is critical to avoid having your experts excluded before trial. The “junk science” narrative J&J deployed in this Los Angeles trial is, at its core, a Sargon/Daubert challenge dressed up for the jury — an argument that the plaintiff’s expert opinions are not reliable enough to be believed.
The Evidence Clock — What Exists and How Fast It Dies
In a talc-ovarian cancer case, the evidence that decides the outcome is perishable. Some of it is already gone. The rest is aging. Here is what exists, who holds it, and how fast it can legally disappear.
Decedents’ talc product containers and lot numbers. If your loved one kept the actual bottle or box of Johnson’s Baby Powder she used, that container is evidence — it establishes specific product identification and may enable asbestos or mineralogical testing of any remaining powder. But product containers are routinely discarded after a death. Family members cleaning out a home do not think to save a bottle of baby powder. If any container survives, it must be secured immediately — not next month, not after the estate is settled, now. Once it is gone, you cannot get it back.
Complete medical and pathology records. Your loved one’s medical records document the ovarian cancer diagnosis, the tumor’s cell type and histology, the staging, the treatment course, and — critically — the exclusion of alternative risk factors. Pathology slides and blocks enable independent expert review — a second set of eyes on the tissue itself. Hospital record retention periods vary, and pathology slides and blocks have their own disposal protocols. These should be requested before those protocols activate. In California, patients and their authorized representatives have a right to obtain their medical records — and in a wrongful death case, the personal representative of the estate can exercise that right.
Detailed exposure history via family witness statements. Specific causation — the proof that talc caused THIS woman’s cancer — requires a detailed exposure history: how long she used the product, how frequently, what brands, and the method of application. This testimony comes from family members, cohabitants, and caregivers. Their memories are degrading right now. The co-worker who remembers her dusting her uniform with baby powder every morning. The daughter who watched her apply it after every shower. The friend who shared a bathroom on vacation and saw the bottle on the counter. Each of these recollections becomes less specific with every month that passes. They should be interviewed and documented while the details are still sharp.
J&J internal corporate documents. The internal documents — testing memos, safety analyses, FDA communications, marketing strategy papers, and any documents weighing litigation risk against labeling changes — are the engine of failure-to-warn, fraud, and punitive damages theories. These have already been produced in extensive discovery in the coordinated litigation. Access depends on protective orders and prior production. But they are not perishable in the same way — they exist in the litigation record. The challenge is obtaining access through the MDL or coordinated proceedings.
Epidemiological and toxicological expert opinions. Your experts must satisfy California’s Sargon standard for admissibility. Early expert engagement is critical — not after the case is filed, but during the intake and evaluation phase. If your experts are excluded, you may have no case at all, no matter how strong the exposure history is. The defense’s “junk science” strategy is, at its core, an effort to keep your experts out of the courtroom.
The Medicine — Ovarian Cancer’s Trajectory and What It Costs
Ovarian cancer is one of the most lethal gynecologic malignancies. It is often diagnosed late — not because doctors are careless, but because the symptoms (bloating, abdominal pain, early satiety, urinary urgency) are vague and overlap with common gastrointestinal complaints. By the time many women are diagnosed, the disease has already spread beyond the ovaries.
The treatment trajectory is well documented. Diagnostic imaging — typically transvaginal ultrasound and CT scans — is followed by surgical intervention, usually a bilateral salpingo-oophorectomy with staging laparotomy: removal of both ovaries, both fallopian tubes, and often the uterus, along with sampling of lymph nodes and peritoneal surfaces. Surgery is typically followed by platinum-based chemotherapy regimens — carboplatin and paclitaxel — given in cycles over several months. For many women, the cancer recurs. Recurrence may be treated with additional chemotherapy, targeted therapies, or clinical trials. Eventually, for the women who do not survive, the progression reaches palliative care and terminal stages.
This trajectory generates substantial medical expenses — surgical costs, chemotherapy costs, hospitalization for complications, imaging, laboratory work, and specialist visits. It generates profound pain and suffering — the physical pain of surgery and chemotherapy, the nausea and fatigue, the hair loss, the fear of recurrence, the knowledge that the disease is likely to return. And it generates the losses a wrongful death and survival action capture: the financial support the family no longer receives, the companionship and guidance the children no longer have, and the years of life that were taken.
A life-care planner builds the cost stream — past and future medical care, lost earning capacity, the replacement cost of household services the decedent performed. A forensic economist reduces it to present value. These professionals turn “what happened to our family” into a number a jury can evaluate — and the number is almost always far larger than the defense’s first settlement offer.
The Defense Playbook — What J&J’s Lawyers Do and How to Counter It
The Los Angeles verdict is a window into Johnson & Johnson’s trial strategy. Here are the plays — and the counters.
Play 1: The “junk science” attack on general causation. J&J’s litigation leadership publicly characterized the plaintiffs’ causation evidence as “junk science.” This is not just a press strategy — it is a courtroom strategy. The defense attacks the epidemiological studies, arguing the relative risk increases are modest and the studies are subject to recall bias (women who developed cancer may over-report their talc use). It challenges the biological plausibility of talc particle translocation to the ovaries. And it argues the IARC Group 2B classification is too weak to support a causal finding.
The counter: front-load general causation with board-certified epidemiologists who can articulate the biological plausibility of talc particle translocation and integrate it with the epidemiological literature. Meet the recall-bias argument with studies that controlled for it. Meet the “possibly carcinogenic” framing with the observation that the world’s leading cancer-research agency found enough evidence to classify it at all — and that the FDA does not require any pre-market safety testing of cosmetic talc, meaning the regulatory system never assessed the risk before the product reached consumers.
Play 2: The alternative-cause defense. The defense identifies every other risk factor for ovarian cancer the decedent had — age, family history, nulliparity, hormone use, genetic mutations — and argues the cancer came from one of those, not from talc. This is the differential diagnosis battle: the plaintiff’s expert must rule out alternative causes, and the defense’s expert must raise reasonable doubt about each one.
The counter: a specific causation opinion built on a thorough differential diagnosis that documents and addresses each alternative risk factor. If the decedent was BRCA-negative, that eliminates the strongest genetic alternative cause. If she had no family history of ovarian or breast cancer, that weakens the hereditary argument. The exposure history — duration, frequency, method of talc use — is the specific causation anchor that ties the general science to this individual.
Play 3: The bankruptcy-and-delay strategy. J&J’s three failed bankruptcy attempts were not just about forcing a global settlement — they were about delay. Every year of delay means more evidence disappearing, more memories fading, more statutes of limitations running. The company’s own litigation strategy is, in part, a war of attrition against the evidence.
The counter: move fast. Preserve evidence the day you call. Document exposure histories while memories are sharp. Request medical records before retention protocols thin them. File before the statute of limitations bars the claim. The company’s delay strategy only works if you let it.
Play 4: The venue strategy. J&J tries cases in jurisdictions where it believes it can win — and the Los Angeles verdict, coming after an Oklahoma win the prior week, suggests the company is building a record of defense verdicts to strengthen its settlement position. But the company has also lost in venues where the causation proof was strong and the internal documents were persuasive.
The counter: venue matters. California’s strict product liability doctrine, its lack of non-economic damage caps in product liability cases, its punitive damages availability, and its plaintiff-favorable jury pools in many counties make it a strategically significant forum — even though this particular Los Angeles verdict demonstrates that plaintiff-favorability is not uniform and that causation-proof rigor can overcome venue advantages.
Play 5: The “we stopped selling it” narrative. J&J discontinued talc-based baby powder in the United States in 2020, switching to a cornstarch formulation. The company publicly attributed the change to consumer preference. But in the litigation, the 2020 withdrawal is a central evidentiary fact — a jury can infer that a company does not reformulate a product it has sold for over a century unless it has reason to be concerned about the safety of the original formulation.
The counter: use the withdrawal as evidence — not of admission, but of corporate knowledge. The timing of the withdrawal, the internal deliberations that led to it, and any documents connecting the withdrawal to litigation risk or safety concerns are all discoverable and potentially admissible.
How a Talc Case Is Actually Built — From Intake to Resolution
Here is the chronological walk of how a talc-ovarian cancer wrongful death case is actually built — not a summary, but the real process.
Week one: intake and evidence preservation. The day a family calls, the intake begins. Who used the product? What brand? How long? How frequently? What method of application? When was the cancer diagnosed? What was the cell type and stage? What was the treatment course? When did she die? Who is the personal representative of the estate? Are there surviving family members who are statutory beneficiaries under California’s wrongful death statute? The preservation letter goes out — ordering the company, any relevant third parties, and any medical providers to freeze records, product containers, and any physical evidence.
Weeks two through four: records collection. Complete medical records are requested — diagnostic imaging, surgical pathology, chemotherapy records, hospitalization records, palliative care records, and death certificate. Pathology slides and blocks are requested for independent expert review. The decedent’s pharmacy records, gynecologic history, and genetic testing results (if any) are obtained to build the differential diagnosis and rule out alternative causes.
Months one through three: exposure history documentation. Family members, cohabitants, and caregivers are interviewed — on the record, with specificity. When did she start using talc? Was it Johnson’s Baby Powder specifically, or another brand? Was it daily, weekly, sporadic? Did she apply it to the perineal area? Did she use it after showers, after baths, on hot days, regularly? Did anyone else in the household use it? Are there photographs, receipts, or subscription records that corroborate the usage? Each of these details is a link in the specific causation chain.
Months three through six: expert engagement. A board-certified gynecologic oncologist reviews the pathology and provides a specific causation opinion. An epidemiologist provides the general causation framework. A toxicologist addresses the biological mechanism. Each expert’s methodology is evaluated against California’s Sargon standard to ensure admissibility. If the defense is likely to challenge an expert’s qualifications or methodology, that challenge is anticipated and addressed before the expert’s deposition.
Months six through twelve: discovery and corporate documents. If the case is in the coordinated litigation or the MDL, internal corporate documents are obtained through the established discovery track. If the case is an individual filing, targeted discovery requests seek testing memos, safety analyses, FDA communications, and marketing strategy documents. The documents that show what the company knew — and when — are the spine of the failure-to-warn and punitive damages theories.
Year one through resolution: depositions, motions, and trial preparation. Corporate witnesses are deposed — the scientists who tested the talc, the executives who decided whether to warn, the marketing personnel who promoted the product. Expert depositions lock in the causation opinions. Pretrial motions address the choice of legal theories — strict liability, negligence, failure to warn, fraud — and the admissibility of evidence. And then, if the case does not settle, it goes to a jury.
The number at the end — the settlement or verdict — is built from all of it. From the exposure history that ties the general science to this individual. From the pathology that rules out alternative causes. From the corporate documents that show what the company knew. From the experts who can withstand cross-examination. And from the jury — twelve people from the reader’s own community who decide whether the evidence is enough.
What Your Case Might Be Worth — Honest Evaluation
We are not going to promise you a number. We are going to tell you the truth about the range, and the truth is that the range is extreme.
At the low end: $0. A defense verdict, as happened in this Los Angeles trial, means the family recovers nothing. Three wrongful death claims yielded zero because ten of twelve jurors were not persuaded the company was negligent. That is the risk. It is real. If you want to understand what happens when a case does not succeed, this video explains it plainly.
At the high end: $10 million to $100 million or more for successful single-decedent and multi-decedent ovarian cancer talc verdicts nationally, varying by jurisdiction, number of plaintiffs, and punitive damage findings. The Ingham verdict — 22 plaintiffs — produced an original jury award of $4.69 billion, reduced on appeal to approximately $2.12 billion, and that reduced award was affirmed when the U.S. Supreme Court declined to review it. That is the largest talc verdict on record, and it stood.
Between those extremes, the value of your specific case depends on: the duration and frequency of talc use (longer and more frequent is stronger), the completeness of the exposure history (documented by multiple witnesses is stronger), the availability of product containers (physical evidence is stronger than testimony alone), the quality of medical documentation (pathology that rules out alternative causes is stronger), the presence of internal corporate documents showing what the company knew (the punitive damages engine), and the venue where the case would be filed.
Past results depend on the facts of each case and do not guarantee future outcomes. That is not a disclaimer we put in fine print — it is the truth. What we can tell you is what the range looks like, what drives a case toward the high end or the low end, and what your specific facts look like when measured against those drivers. This video walks through how case value is actually calculated.
The First 72 Hours — What to Do Now
If you are reading this because your mother, your wife, your sister, or your daughter used talc-based baby powder and died of ovarian cancer — or was diagnosed with ovarian cancer and is still fighting — here is what to do in the next 72 hours.
Day one: secure physical evidence. Search the home, the bathroom, the closets, the storage boxes. Look for any remaining containers of Johnson’s Baby Powder or any other talc-based body powder. If you find one, do not open it, do not shake it, do not throw it away. Place it in a sealed plastic bag and store it in a safe location. This container — with its lot number, its packaging, and any remaining powder — is potentially testable for asbestos contamination and is the single strongest piece of product identification evidence you can have.
Day one: request medical records. Contact every hospital, oncology practice, and imaging center that treated your loved one. Request the complete medical record — not just the discharge summary, but the full chart: imaging reports, pathology reports, surgical operative notes, chemotherapy administration records, laboratory results, and physician notes. Request the pathology slides and blocks specifically — these are the tissue samples that an independent expert can re-examine. Hospital record retention is not infinite. Make the request in writing.
Day two: document the exposure history. Sit down with every family member, cohabitant, and close friend who can describe your loved one’s talc use. Write down what they remember — the brand, the frequency, the duration, the method of application, where the bottle was kept, when she started, when (if ever) she stopped. Do this now, while the memories are specific. “She used it every day after her shower for as long as I can remember” is powerful testimony. “She used it sometimes, I think, maybe for years” is not. The difference is specificity, and specificity fades with time.
Day two: identify the personal representative. In California, a wrongful death claim is brought by the personal representative of the decedent’s estate — the person the court appoints to manage the estate and bring claims on behalf of the family. If your loved one’s estate has not been opened in probate court, that is one of the first legal steps. We handle that appointment.
Day three: call a lawyer. Not next month. Not after the estate is settled. Not after you have “had time to think about it.” The statute of limitations is running. The evidence is fading. The witnesses’ memories are degrading. And the company — which has 67,000 cases to manage and a demonstrated strategy of delay — is counting on the passage of time to work in its favor. The call is free. The consultation is free. And we do not get paid unless we win your case.
Frequently Asked Questions
Does this Los Angeles verdict mean my talc case is over?
No. This was one trial of three wrongful death claims on a negligence theory in one courtroom. Over 67,000 talc cases remain pending against Johnson & Johnson. The company has won some trials and lost others — including a $2.1 billion verdict that was affirmed when the U.S. Supreme Court declined to review it. Your case’s viability depends on your specific facts: the duration and frequency of talc use, the quality of your medical documentation, the availability of product containers and exposure witnesses, and the legal theories your attorney chooses to pursue.
How long do I have to file a talc ovarian cancer lawsuit?
California’s statute of limitations for wrongful death is generally two years from the date of death. For personal injury claims (if your loved one is still living), the deadline is generally two years from the date the injury was discovered or should have been discovered. In toxic exposure cases, the discovery rule may affect timing — the clock may not start until you knew or reasonably should have known that talc exposure caused the cancer. This is jurisdiction-specific and fact-dependent. You must confirm the current California rule for your specific situation with an attorney immediately. Waiting to “see how you feel about it” is how good cases die quietly.
What if my loved one already passed away and I cannot find any talc containers?
Product containers are strong evidence but not the only evidence. Exposure history — documented through family witness statements, photographs, receipts, subscription records, and consistent testimony from multiple sources — can establish product identification and usage patterns. The absence of a physical container makes the case harder but does not make it impossible. What matters most is how quickly the exposure history is documented while memories are still specific.
Does California law allow punitive damages in talc cases?
Yes. California allows punitive damages upon a showing of malice, oppression, or fraud. In talc litigation, punitive damages theories rest on internal corporate documents — memoranda, testing results, emails, and strategy papers suggesting the company knew of contamination concerns or cancer risk and chose not to warn consumers. Prior talc verdicts nationally have included significant punitive awards. The $2.1 billion affirmed Ingham verdict included a substantial punitive component. Whether punitive damages are available in your specific case depends on the evidence of corporate conduct.
Why was this case tried on negligence instead of strict liability?
The specific reasons reflect strategic pleading decisions or pretrial rulings made by the plaintiffs’ attorneys in that case. What matters for you is that California’s strict products liability doctrine — the Greenman doctrine — does not require proof of negligence at all. Under strict liability, the question is whether the product was defective (including whether it lacked adequate warnings), not whether the company was careless. Experienced talc litigators are studying this verdict and considering whether strict liability failure-to-warn theories may present a more favorable liability framework in future ovarian cancer talc trials.
What if my loved one had other risk factors for ovarian cancer?
This is the defense’s strongest argument — and it is why specific causation is the battleground. Ovarian cancer has many known risk factors: BRCA mutations, family history, age, nulliparity, hormone therapy, endometriosis. The defense will identify every risk factor your loved one had and argue the cancer came from one of those, not from talc. The plaintiff’s expert counters with a differential diagnosis — a systematic evaluation that documents and addresses each alternative cause. If your loved one was BRCA-negative, had no family history of ovarian or breast cancer, and had a long, well-documented history of perineal talc use, the alternative-cause argument is weakened. The specific facts of your case determine how this fight plays out.
How much does it cost to hire a talc lawsuit attorney?
Nothing up front. We work on contingency — 33.33 percent before trial and 40 percent if the case goes to trial. We do not get paid unless we win your case. The consultation is free. The call is free. There is no hourly billing, no retainer, no out-of-pocket cost to you for the investigation, the experts, the discovery, or the trial preparation. Those costs are advanced by the firm and recovered from the recovery if there is one. If there is no recovery, you owe us nothing for our time.
Is it too late if the talc exposure happened decades ago?
Not necessarily. The discovery rule — which many states apply in toxic exposure cases — means the statute of limitations may not start running until you knew or reasonably should have known that the talc exposure caused the cancer. For a woman who used talc in the 1970s and 1980s but was not diagnosed with ovarian cancer until recently, the clock may have started recently, not decades ago. But this rule is jurisdiction-specific, and some states impose an outer deadline (a statute of repose) that can cut off a claim even before discovery. You must confirm the current rule in your state with an attorney — do not assume it is too late without checking.
Can I still file a claim if my loved one used generic or store-brand talc powder?
Potentially, but the defendant changes. If the product was Johnson’s Baby Powder, Johnson & Johnson is the defendant. If it was a store brand or generic talc powder, the manufacturer of that specific product is the defendant — and identifying that manufacturer, proving product identification, and assessing that company’s resources and insurance are separate challenges. Some cases involve multiple products used over time, which can mean multiple defendants. The exposure history must identify specific brands and time periods as precisely as possible.
What is the difference between a talc case and a mesothelioma case?
Mesothelioma is a rare cancer that is almost exclusively caused by asbestos exposure. If a talc product was contaminated with asbestos and the user developed mesothelioma, the causal link is comparatively straightforward — mesothelioma is a “signature disease” for asbestos. Ovarian cancer is not a signature disease for talc. It has many known causes, and the causal link between talc and ovarian cancer is more contested. This is why J&J has settled most mesothelioma cases but is fighting the ovarian cancer cases — the causation battle is harder. It is not impossible — juries have returned multi-billion-dollar verdicts for ovarian cancer plaintiffs — but it requires stronger expert testimony and more thorough specific causation proof.
Why This Firm
We are Attorney911 — The Manginello Law Firm, PLLC. We are Legal Emergency Lawyers. We have been in courtrooms for over 24 years, and we take California cases.
Ralph Manginello is our managing partner — 27-plus years licensed, admitted in Texas state courts and the U.S. District Court for the Southern District of Texas, a journalist before he was a lawyer, and a competitor who hates losing. He leads our practice areas with the instinct of someone who has spent decades studying how corporations defend themselves and how to break through those defenses.
Lupe Peña is our associate attorney — a former insurance-defense attorney who spent years inside a national defense firm, in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows how the other side prices a case, how it selects IME doctors, how it conducts surveillance, and how it uses delay as a weapon. He now uses that knowledge for injured clients. And he conducts full consultations in Spanish — without an interpreter.
We serve your family fully in Spanish. Hablamos Español.
We work on contingency. We do not get paid unless we win your case. The call costs nothing. The consultation costs nothing. The number is 1-888-ATTY-911 — 1-888-288-9911. We answer 24 hours a day, seven days a week, with live staff — not an answering service.
If we are not the right fit for your case, we will tell you. If the evidence is not there, we will tell you that too. What we will not do is tell you a defense verdict in one Los Angeles courtroom means your family’s case is over — because it does not. 67,000 cases are still pending. The science is still being fought. The company’s own internal documents are still in the litigation record. And the evidence that decides whether your case is strong or weak is aging — right now, while you are reading this.
Call us. Let us look at your facts. Let us tell you honestly where you stand. The call is free. The consultation is free. And we do not get paid unless we win your case.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Contacting the firm is free and confidential.